2024
Medial prefrontal cortex neurotransmitter abnormalities in posttraumatic stress disorder with and without comorbidity to major depression
Swanberg K, Prinsen H, Averill C, Campos L, Kurada A, Krystal J, Petrakis I, Averill L, Rothman D, Abdallah C, Juchem C. Medial prefrontal cortex neurotransmitter abnormalities in posttraumatic stress disorder with and without comorbidity to major depression. NMR In Biomedicine 2024, 37: e5220. PMID: 39054694, DOI: 10.1002/nbm.5220.Peer-Reviewed Original ResearchPosttraumatic stress disorderMedial prefrontal cortexStress disorderPosttraumatic stress disorder patientsPosttraumatic stress disorder diagnosisChronic psychiatric conditionImpact of psychiatric comorbiditiesComorbid MDDPrefrontal cortexDepressive disorderTraumatic stressorsPsychiatric conditionsMDDPsychiatric comorbiditiesNeurotransmitter abnormalitiesConcentrations of glutamateMetabolite abnormalitiesHealthy controlsDisordersPattern of abnormalitiesParticipantsGlutamateIn vivo protonMetabolic abnormalitiesDepression
2018
Pharmacological and Psychological Treatments for Comorbid Alcohol Use Disorder and Depressive Disorder: a Review
Yoon G, Petrakis I. Pharmacological and Psychological Treatments for Comorbid Alcohol Use Disorder and Depressive Disorder: a Review. Current Addiction Reports 2018, 5: 312-322. DOI: 10.1007/s40429-018-0213-z.Peer-Reviewed Original ResearchComorbid alcohol use disorderAlcohol use disorderPsychological interventionsCognitive-behavioral treatmentUse disordersPsychological treatmentDepressive disorderMotivational interviewingComorbid disordersMixed resultsDisordersInterventionRecent FindingsWePharmacological interventionsCurrent reviewEffective treatmentFurther researchReviewThe goalInterviewingAntidepressantsPatientsTreatmentDepressionTrialsEfficacy
2013
Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence
Ralevski E, Jane J, O’Brien E, Edens E, Arnaout B, Kerfoot K, Keegan K, Weiner J, Russo M, Petrakis I. Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence. Journal Of Dual Diagnosis 2013, 9: 301-310. DOI: 10.1080/15504263.2013.835163.Peer-Reviewed Original ResearchDepressive symptomsAlcohol dependenceDual diagnosisRates of smokingMain outcome variablesSymptoms of depressionTreatment of peopleTreatment trialsComorbid depressionMecamylamineSide effectsNonsmokersSmokingSymptomsOutcome variablesBest treatmentDrinking outcomesDepressionPlaceboSmokersFurther studiesSignificant differencesDiagnosisParticipantsTreatment
1998
Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts
Petrakis I, Carroll K, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug And Alcohol Dependence 1998, 50: 221-226. PMID: 9649975, DOI: 10.1016/s0376-8716(98)00032-5.Peer-Reviewed Original ResearchConceptsCocaine useOpioid addictsMedication effectsDepressive symptomsSignificant decreaseEffectiveness of fluoxetineSelf-reported cocaine useDrug use outcomesSubsample of subjectsFluoxetine treatmentUrine toxicologySelf-reported useDepressive disorderSevere depressionHeroin useFluoxetineEffective agentUse outcomesDepressionPlaceboSignificant differencesTreatmentSymptomsAddictsMethadone
1995
Fluoxetine Treatment for Dually Diagnosed Methadone Maintained Opioid Addicts:
Petrakis I, Carroll K, Gordon L, Cushing G, Rounsaville B. Fluoxetine Treatment for Dually Diagnosed Methadone Maintained Opioid Addicts:. Journal Of Addictive Diseases 1995, 13: 25-32. PMID: 7734457, DOI: 10.1300/j069v13n03_03.Peer-Reviewed Original Research